New hope for rare penile cancer: targeted drug combo shows promise
NCT ID NCT07054307
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new two-drug combination (MRG003 and HX008) as a first treatment for advanced penile cancer that has spread. It aims to be more effective and less toxic than standard chemotherapy. The study enrolls 10 men with a specific type of cancer (EGFR-positive) who have not had prior treatment for advanced disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PENILE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
- Penis transplants could restore form and function for wounded warriors
- New drug combo targets HPV-Driven cancers in phase II trial
- Double antibody attack: early trial combines immune and Growth-Signal blockers against advanced cancers
- Triple immunotherapy attack shows promise against Hard-to-Treat HPV cancers
- Promising drug cocktail aims to shrink penile cancer before surgery